II.f

Hypoxemia, low oxygen saturation (may occur in isolation)

(Fr: hypoxémie/désaturation isolée). Hypoxemia may reflect 1) Deteriorated VA/Q indicating early lung injury, cell sequestration in the distal pulmonary circulation 2) Ventilatory depression (see under IX a, c, d, e), in this case typically associated with a raise in arterial PCO2. See also under methemoglobinemia, a condition that commonly alters SpO2 readings. Rare instances of spurious hypoxemia from oxygen steal or larceny were described in high-WBC-acute leukemia patients receiving ATRA. Postoperative reopening of the foramen ovale may cause severe hypoxemia, sometimes positional (PMID 30619614)

Last update : 01/01/1970
 

Causative drugs

24

Ado-trastuzumab emtansine

1

All-transretinoic acid (ATRA)

1

Anabolic androgenic steroids

I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia (subacute, acute) I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic II.f II - Pulmonary edema - Acute lung injury - ARDS
II.f - Hypoxemia, low oxygen saturation (may occur in isolation) III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.x IV - Airway involvement
IV.x - Transient hacking cough VI.e VI - Pulmonary vasculopathies
VI.e - Fat/oil embolism - The FES embolism syndrome X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease (subacute, chronic) XII.v XII - Cardiovascular involvement / toxicity
XII.v - Hypertrophic cardiomyopathy XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XV.n XV - Pathology
XV.n - Path: Pulmonary alveolar proteinosis pattern (PAP pattern) XV.p XV - Pathology
XV.p - Path: Exogenous lipoid pneumonia XV.bu XV - Pathology
XV.bu - Path: Pulmonary peliosis
1

Cardioversion (electrical)

1

Codeine

1

Epoprostenol

1

Ethylene-vinyl alcohol copolymer (e.g. Onyx (R))

1

G/GM-CSF

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.f II - Pulmonary edema - Acute lung injury - ARDS
II.f - Hypoxemia, low oxygen saturation (may occur in isolation) IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.e VI - Pulmonary vasculopathies
VI.e - Fat/oil embolism - The FES embolism syndrome X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome) X.ao X - Systemic/Distant conditions, syndromes and reactions
X.ao - Flare of preexisting vasculitis XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis XII.at XII - Cardiovascular involvement / toxicity
XII.at - Aortitis XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
2

Hemodialysis - Chronic renal replacement therapy

1

Hemotherapy (transfusion/infusion of whole blood, red cells, platelets, or blood products)

I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.e II - Pulmonary edema - Acute lung injury - ARDS
II.e - Transfusion-related acute lung injury (TRALI) (May cause ARDS) II.f II - Pulmonary edema - Acute lung injury - ARDS
II.f - Hypoxemia, low oxygen saturation (may occur in isolation) II.h II - Pulmonary edema - Acute lung injury - ARDS
II.h - Overload pulmonary edema (including posttransfusional (TACO)) III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.i VI - Pulmonary vasculopathies
VI.i - Acute pulmonary hypertension VI.n VI - Pulmonary vasculopathies
VI.n - Crystal pulmonary embolism VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XII.j XII - Cardiovascular involvement / toxicity
XII.j - Myocardial stunning XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa) XV.w XV - Pathology
XV.w - Path: Pulmonary edema (see also II/IIa) XV.aj XV - Pathology
XV.aj - Path: Cholesterol crystal embolism XV.at XV - Pathology
XV.at - Path: Pulmonary capillary granulocyte sequestration XVI.d XVI - Imaging
XVI.d - Imaging: Alveolar opacities or haze with a batwing or butterfly distribution XVII.ad XVII - Infections & related conditions
XVII.ad - Systemic infection (transmitted)
1

Hydrochloric acid fumes

1

Hydrochlorothiazide

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic II.f II - Pulmonary edema - Acute lung injury - ARDS
II.f - Hypoxemia, low oxygen saturation (may occur in isolation) II.i II - Pulmonary edema - Acute lung injury - ARDS
II.i - Flash (fulminate) pulmonary edema II.r II - Pulmonary edema - Acute lung injury - ARDS
II.r - Interstitial pulmonary edema IX.h IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.h - Dyspnea, unexplained otherwise X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs) X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension XXI.a XXI - Rechallenge data
XXI.a - Rechallenge can lead to near-fatal or fatal relapse of AE/ILD
1

Iloprost

1

Ketamine

1

Lipids (parenteral)

1

Liposuction

1

Methadone

I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis (silicosis, talcosis...) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.f II - Pulmonary edema - Acute lung injury - ARDS
II.f - Hypoxemia, low oxygen saturation (may occur in isolation) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.g VI - Pulmonary vasculopathies
VI.g - Foreign body pulmonary vasculopathy (Excipient lung disease) IX.c IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.c - Chest wall muscle rigidity - Stiff/wooden chest IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis) IX.e IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.e - Disordered breathing pattern - Cheynes-Stokes respiration IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.p XII - Cardiovascular involvement / toxicity
XII.p - QTc prolongation XII.t XII - Cardiovascular involvement / toxicity
XII.t - Torsades de pointe XII.bo XII - Cardiovascular involvement / toxicity
XII.bo - Right ventricular dysfunction.failure
2

Metoprolol

1

Nimodipine

1

Nitric oxide (NO)

4

Obatoclax

1

Propofol

II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.f II - Pulmonary edema - Acute lung injury - ARDS
II.f - Hypoxemia, low oxygen saturation (may occur in isolation) II.i II - Pulmonary edema - Acute lung injury - ARDS
II.i - Flash (fulminate) pulmonary edema IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.b IV - Airway involvement
IV.b - Bronchospasm and angioedema IV.d IV - Airway involvement
IV.d - Cough (lone) IV.e IV - Airway involvement
IV.e - Cough (acute, violent, explosive) IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) VI.e VI - Pulmonary vasculopathies
VI.e - Fat/oil embolism - The FES embolism syndrome VIII.h VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.h - Vocal cord dysfunction, adduction, closure, injury IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis) IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea IX.p IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.p - Disordered breathing during sleep - Sleep apnea X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) X.aa X - Systemic/Distant conditions, syndromes and reactions
X.aa - Propofol infusion syndrome (PRIS) XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning XI.x XI - Miscellaneous
XI.x - Addictive risk XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension XII.w XII - Cardiovascular involvement / toxicity
XII.w - Asystole XV.ae XV - Pathology
XV.ae - Path: Lipid/fat embolism (see also VIe) XXIV.h XXIV - Veterinary medicine
XXIV.h - Veterinary: Anaphylaxis/Anaphylactoid reaction
1

Talc (inhaled, sniffed, i.v., intrapleural)

I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis (silicosis, talcosis...) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.f II - Pulmonary edema - Acute lung injury - ARDS
II.f - Hypoxemia, low oxygen saturation (may occur in isolation) IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx) IV.i IV - Airway involvement
IV.i - Foreign body aspiration bronchiolitis IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening V.r V - Pleural and/or pericardial involvement
V.r - Pleural mass or masses VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.g VI - Pulmonary vasculopathies
VI.g - Foreign body pulmonary vasculopathy (Excipient lung disease) VII.f VII - Mediastinal involvement
VII.f - An enlarged or dense thymus VII.n VII - Mediastinal involvement
VII.n - Mediastinal talcoma X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.u XI - Miscellaneous
XI.u - Chest pressure/discomfort XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.q XV - Pathology
XV.q - Path: Foreign body deposits/granulomatous reaction XV.s XV - Pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma) XV.ag XV - Pathology
XV.ag - Path: Foreign body embolism, microangiopathy, vasculopathy XV.da XV - Pathology
XV.da - Path: Birefringent particles in lung tissue and/or cells XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules XVI.ae XVI - Imaging
XVI.ae - Imaging: A pattern similar to pneumoconiotic progressive massive fibrosis (PMF) XVI.bm XVI - Imaging
XVI.bm - Imaging: Avid pleural uptake on PET-scan XVIII.i XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.i - Eye-catcher: Tracer-avid pleural area or areas on PET-CT XIX.k XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.k - BAL: Talc crystals in macrophages or lying free in BALF
1

Vasodilators, systemic

1

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies